0001209191-24-000431.txt : 20240103
0001209191-24-000431.hdr.sgml : 20240103
20240103164950
ACCESSION NUMBER: 0001209191-24-000431
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240103
DATE AS OF CHANGE: 20240103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Campbell David Alan
CENTRAL INDEX KEY: 0001864158
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40475
FILM NUMBER: 24507592
MAIL ADDRESS:
STREET 1: C/O JANUX THERAPEUTICS, INC.
STREET 2: 11099 N. TORREY PINES ROAD, SUITE 290
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Janux Therapeutics, Inc.
CENTRAL INDEX KEY: 0001817713
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 822289112
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10955 VISTA SORRENTO PARKWAY
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 751-4493
MAIL ADDRESS:
STREET 1: 10955 VISTA SORRENTO PARKWAY
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-02
0
0001817713
Janux Therapeutics, Inc.
JANX
0001864158
Campbell David Alan
C/O JANUX THERAPEUTICS, INC.
10955 VISTA SORRENTO PARKWAY, SUITE 200
SAN DIEGO
CA
92130
1
1
0
0
President and CEO
0
Stock Option (right to buy)
11.02
2024-01-02
4
A
0
356500
0.00
A
2034-01-01
Common Stock
356500
356500
D
25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period.
/s/ Maria Dobek, Attorney-in-Fact
2024-01-03